However, for late-stage breast cancer patients, the efficacy of current treatments is limited; these treatments include cancer immunotherapy, such as immune checkpoint inhibitors targeting programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (5–7). Here, PDCD1 is linked to breast cancer.